Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure

Nimer Alkhatib, Nancy K. Sweitzer, Christopher S. Lee, Brian Erstad, Marion Slack, Mahdi Gharaibeh, Jason Karnes, Walter Klimecki, Kenneth Ramos, Ivo Abraham

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure'. Together they form a unique fingerprint.

Medicine & Life Sciences